title: Endometrial HOXA10 expression after controlled ovarian hyperstimulation with recombinant follicle-stimulating hormone.
abstract: OBJECTIVE
  To determine the effects of controlled ovarian hyperstimulation and resultant high levels of E(2) on endometrial HOXA10 expression (a marker of endometrial receptivity).
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  University academic medical center.
  
  
  METHODS
  Twenty-five women undergoing controlled ovarian hyperstimulation with recombinant FSH and 30 fertile controls.
  
  
  METHODS
  Endometrium was obtained by Pipelle endometrial biopsy on cycle days 21-25. In addition, Ishikawa cells (a well-differentiated endometrial adenocarcinoma cell line) were treated with either E(2), recombinant FSH, GnRH agonist, or GnRH antagonist. RNA was extracted and analyzed by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR).
  
  
  METHODS
  HOXA10 expression.
  
  
  RESULTS
  Endometrial HOXA10 expression in women undergoing controlled ovarian hyperstimulation (COH) with recombinant FSH was not different from that in fertile controls. Estradiol increased HOXA10 expression in Ishikawa cells in a dose-dependent manner from 10(-9) to 10(-7) M. Neither recombinant FSH, GnRH agonist, nor GnRH antagonist altered HOXA10 expression in these cells.
  
  
  CONCLUSIONS
  Controlled ovarian hyperstimulation did not inhibit endometrial HOXA10 expression in vivo. In addition, in vitro endometrial cell HOXA10 expression was not altered by either recombinant FSH, GnRH agonist, or GnRH antagonist. COH is unlikely to adversely impact endometrial receptivity.
mesh_terms: D000328:Adult; D010064:Embryo Implantation / Q000187:drug effects / Q000502:physiology; D004717:Endometrium / Q000187:drug effects / Q000378:metabolism*; D004958:Estradiol / Q000378:metabolism; D005260:Female; D005300:Fertility Agents, Female / Q000378:metabolism; D005640:Follicle Stimulating Hormone / Q000494:pharmacology*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000378:metabolism; D000080905:Homeobox A10 Proteins; D018398:Homeodomain Proteins / Q000096:biosynthesis* / Q000235:genetics; D006727:Hormone Antagonists / Q000378:metabolism; D006801:Humans; D016729:Leuprolide / Q000378:metabolism; D010062:Ovulation Induction; D011446:Prospective Studies; D012313:RNA / Q000737:chemistry / Q000235:genetics; D011994:Recombinant Proteins / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured
chemical_list: D005300:Fertility Agents, Female; D000080905:Homeobox A10 Proteins; D018398:Homeodomain Proteins; D006727:Hormone Antagonists; D011994:Recombinant Proteins; C092119:Hoxa10 protein, mouse; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D012313:RNA; D005640:Follicle Stimulating Hormone; D016729:Leuprolide; C061018:ganirelix